Nanako Iwami

ORCID: 0000-0001-7262-7791 · 7 papers in corpus
2026
Reproductive medicine and biology ·doi:10.1002/rmb2.70066

PurposeThis study aimed to develop international expert consensus statements on chronic endometritis (CE) through a comprehensive literature review of existing evidence and a modified Delphi approach.MethodsTen panelists of the Japan Societ…

2025
Reproductive medicine and biology ·doi:10.1002/rmb2.12634

PurposeTo evaluate the impact of Endometrial Microbiome Metagenomic Analysis and Analysis of Infectious Chronic Endometritis (EMMA & ALICE) on pregnancy outcomes following recommended treatments in women with recurrent implantation failure …

2023
Journal of assisted reproduction and genetics ·doi:10.1007/s10815-022-02688-6

PurposeA Lactobacillus-dominated microbiota in the endometrium was reported to be associated with favorable reproductive outcomes. We investigated in this study whether 16S ribosomal RNA (rRNA) gene sequencing analysis of the uterine microb…

article 2021
·doi:10.1093/humrep/deab130.762

Abstract Study question What is the perinatal outcome of pregnancies resulting from a controlled ovarian hyperstimulation (COH) regimen of progestin-primed ovarian stimulation (PPOS) protocol using dienogest (DNG) in patients with endometri…

article 2020
Reproductive biology ·doi:10.1016/j.repbio.2020.100470

Dienogest (DNG) is an oral progestin effective for the treatment of symptomatic endometriosis, such as reduction of endometrial lesion and control of pain intensity. Progestin-primed ovarian stimulation (PPOS) is a new controlled ovarian hy…

article 2020
·doi:10.17632/6pncczvb98.4

Study question Is it effective for patients taking dienogest to use progestin-primed ovarian stimulation (PPOS) protocol during controlled ovarian hyperstimulation (COH), compared to PPOS with dydrogesterone (DYG)? Study answer Patients tak…

preprint 2018
·doi:10.26226/morressier.5af300af738ab10027aa94d2